UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 12, 2017
FibroGen, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 001-36740 | | 77-0357827 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
FibroGen, Inc.
409 Illinois Street
San Francisco, CA 94158
(Address of principal executive offices, including zip code)
(415)978-1200
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ☐ | Pre-commencement communications pursuant toRule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant toRule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On September 12, 2017, FibroGen, Inc. presented currently available data from the company’s Phase 2 randomized, double-blind, controlled study in patients with idiopathic pulmonary fibrosis (IPF) in an oral presentation by Luca Richeldi, M.D., Ph.D., Head of the Division of Pulmonary Medicine at Agostino Gemelli University Hospital of the Catholic University of the Sacred Heart in Rome, Italy. The presentation was given at the European Respiratory Society (ERS) International Congress 2017 in Milan, Italy.
A copy of such presentation, entitled “PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab(FG-3019) in IPF patients,” is furnished as Exhibit 99.1 to this Current Report onForm 8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | FIBROGEN, INC. |
| Dated: September 12, 2017 | | | | |
| | | | By: | | /s/ Michael Lowenstein |
| | | | | | Michael Lowenstein |
| | | | | | Chief Legal Counsel |
INDEX TO EXHIBITS
| | |
Exhibit No. | | Description |
| |
| 99.1 | | FibroGen, Inc. presentation dated September 12, 2017, entitled “PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab(FG-3019) in IPF patients.” |
